Functional dyspepsia (FD) is the most common disease in the daily clinical diagnosis and treatment of the Department of Gastroenterology. The main clinical symptoms include epigastric pain, burning sensation, fullness and early satiety after meals, loss of appetite, belching, nausea and vomiting, etc. According to clinical characteristics, FD can also be divided into two subtypes: postprandial discomfort syndrome and epigastric pain syndrome. The prevalence of FD is high. Epidemiological investigation shows that the incidence rate of functional dyspepsia in domestic population is about 20%, which means that about 300 million people in China are deeply troubled by dyspepsia symptoms.

Although FD is a functional disease, it does not pose a threat to the life safety of patients, but recurrent epigastric pain, epigastric flatulence and other symptoms often trouble patients, seriously affecting their work and learning, leading to a decline in the quality of life. In addition, because patients with repeated illness frequently seek medical treatment and examination, a large amount of medical resources are also consumed.

At present, the treatment of FD is mainly based on prokinetic drugs and antacid drugs. Because functional dyspepsia is often accompanied by decreased gastric motility, if patients have symptoms after meals, they will first use prokinetic drugs, such as motilium, mosapride, etc. Patients who have symptoms before meals, relieve after meals or have nothing to do with eating, and whose main symptoms are epigastric pain, generally use acid suppressants. Acid suppressants are drugs that can inhibit the secretion of gastric acid, mainly composed of 'tibetidine' and 'prazole' drugs, such as famotidine, omeprazole, etc. However, medicine is a double-edged sword, and it is often easy to bring side effects when treating diseases, such as cardiovascular adverse events, gastrointestinal symptoms and rashes. Especially for patients with basic diseases, medication should be particularly careful.

At present, the treatment of FD is mainly based on prokinetic drugs and antacid drugs. Because functional dyspepsia is often accompanied by decreased gastric motility, if patients have symptoms after meals, they will first use prokinetic drugs, such as motilium, mosapride, etc. Patients who have symptoms before meals, relieve after meals or have nothing to do with eating, and whose main symptoms are epigastric pain, generally use acid suppressants. Acid suppressants are drugs that can inhibit the secretion of gastric acid, mainly composed of 'tibetidine' and 'prazole' drugs, such as famotidine, omeprazole, etc. However, medicine is a double-edged sword, and it is often easy to bring side effects when treating diseases, such as cardiovascular adverse events, gastrointestinal symptoms and rashes. Especially for patients with basic diseases, medication should be particularly careful.

Different from traditional instruments, biofeedback Gastrointestinal motility instrument In addition to the therapeutic function, it can also display various gastrointestinal motility parameters in real time, objectively reflect the gastrointestinal peristalsis and gastrointestinal motility of patients, and can be cross referenced with gastrointestinal endoscopy and other inspection methods, providing objective basis for the treatment and efficacy of gastrointestinal diseases.

At present, the instrument has been used in Jiangsu Provincial People's Hospital, Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing First Hospital and other hospitals, and has achieved good feedback effect.